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Hexamethylene bisacetamide (HMBA) is a potent inducer of cell differentiation and HIV production in chronically
infected cells. However, its mechanism of action remains poorly defined. In this study, we demonstrate that HMBA
activates transiently the PI3K/Akt pathway, which leads to the phosphorylation of HEXIM1 and the subsequent release
of active positive transcription elongation factor b (P-TEFb) from its transcriptionally inactive complex with HEXIM1
and 7SK small nuclear RNA (snRNA). As a result, P-TEFb is recruited to the HIV promoter to stimulate transcription
elongation and viral production. Despite the continuous presence of HMBA, the released P-TEFb reassembles rapidly
with 7SK snRNA and HEXIM1. In contrast, a mutant HEXIM1 protein that cannot be phosphorylated and released from
P-TEFb and 7SK snRNA via the PI3K/Akt pathway antagonizes this HMBA-mediated induction of viral production. Thus,
our studies reveal how HIV transcription is induced by HMBA and suggest how modifications in the equilibrium
between active and inactive P-TEFb could contribute to cell differentiation.
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Introduction
Highly active antiretroviral therapy (HAART) has proven
effectiveagainstprogressiontoAIDS.Indeed,theviralloadscan
be lowered to undetectable levels in peripheral blood of HIV-
infected individuals with this treatment. However, the persis-
tence of latently infected cells in these patients prevents their
cure. Indeed, these cells harbor integrated proviral genomes,
which are insensitive to HAART and can be reactivated upon
treatment interruption. Thus, one of the major therapeutic
goals is to purge these latent reservoirs of HIV.
Proviral latency is established predominantly at the level of
transcription [1,2]. Reactivating viral replication should
render HIV susceptible to HAART and immune elimination.
To this end, initial attempts included treatments with growth
factors such as IL-2 or the activation of T cells with anti-CD3
antibodies, which failed to eradicate HIV and resulted in
deleterious side effects [3,4]. Therefore, alternative ap-
proaches towards the reactivation of HIV must be developed.
They should not induce a global stimulation of lymphocyte
proliferation but activate speciﬁcally HIV transcription. Of
note, prostratin, a compound that activates protein kinase C
(PKC) and NF-jB [5,6], as well as IL-7, a key factor in
lymphocyte homeostasis [7], can activate HIV transcription.
In addition, the inhibition of histone deacetylases (HDACs),
whose recruitment to the HIV promoter has been associated
with transcriptional repression [8], can also activate viral
transcription in peripheral blood mononuclear cells (PBMCs)
from HAART-treated patients using valproic acid [9]. How-
ever, this compound is a weak HDAC inhibitor and despite
encouraging results obtained in four patients [10], the latent
reservoir was not reduced in patients receiving this drug
chronically for neurological conditions [11].
Interestingly, hexamethylene bisacetamide (HMBA), which
is a hybrid bipolar compound that induces terminal differ-
entiation and apoptosis in transformed cells in culture
[12,13], reactivates viral production in chronically infected
cell lines [14,15]. This activation occurs at the level of
transcription and is independent of NF-jB but requires
Sp1-binding sites in the HIV promoter [15]. However, the
mechanism by which HMBA induces HIV transcription
remains unknown. One possible mechanism could involve
increased DNA accessibility and induction of nucleosome
remodeling [16]. However, HMBA neither inhibits HDACs
nor increases histone acetylation [17]. Alternatively, HMBA
could mediate its effects on viral transcription via the
activation of cellular kinases. Indeed, PKC and calcium
pathways are activated by HMBA [18]. In addition, suber-
oylanilide hydroxamic acid (SAHA), a bipolar compound that
is structurally similar to HMBA, activates Akt [19,20].
Importantly, HMBA increases greatly the expression of
HMBA-induced protein 1 (HEXIM1) [21,22] and its homolog
HEXIM2, which, in concert with 7SK small nuclear RNA
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elongation factor b (P-TEFb) in its transcriptionally inactive
complex (large complex [LC]) [23–28]. Besides the LC, P-
TEFb, which is composed of cyclin-dependent kinase 9 (Cdk9)
and cyclin T1 (CycT1), predominantly binds Brd4 [29,30] or is
in a free heterodimeric form (small complex [SC]). As such, P-
TEFb is transcriptionally active and can be recruited to the
HIV promoter to stimulate viral transcription elongation by
phosphorylating the C-terminal domain of RNA polymerase
II (RNAPII) and negative transcription elongation factors
[31,32]. Thus, the exposure of cells to HMBA leads to two
seemingly opposite phenotypes, the induction of HIV tran-
scription and increased levels of HEXIM1 and HEXIM2.
However, it is possible that these events do not occur
simultaneously. Indeed, the partitioning of P-TEFb into
inactive and active complexes is dynamic, and several stress-
inducing agents disrupt the LC and result in the release of P-
TEFb [23,30,33]. Of note, in the course of our studies, it was
demonstrated that HMBA also disrupts the LC, which
resulted in cellular differentiation [34]. However, the nature
of this disruption remains unknown.
In this study, we investigated the mechanism by which
HMBA induces viral production. We found that HMBA
activates Akt transiently via the phosphatidylinositol-3-kinase
(PI3K), leading to the concomitant disruption of the LC and
the recruitment of P-TEFb to the HIV promoter. Impor-
tantly, the inhibition of the PI3K/Akt pathway in chronically
infected cell lines or the expression of a mutant HEXIM1
protein that could not be phosphorylated by Akt, and was
resistant to HMBA-mediated disruption of the LC, antago-
nized the induction of HIV transcription by HMBA. Thus,
our studies reveal how HMBA releases P-TEFb to reactivate
viral production from latency.
Results
HMBA Induces Viral Production in Chronically Infected
Cell Lines and Resting CD4þ T Cells
Since chronically infected U1 (monocytic lineage), ACH-2,
and JDK (lymphocytic lineages) cells represent model systems
for proviral latency in the host, we ﬁrst examined effects of
HMBA on the production of HIV particles in these cells
(Figure 1A). Cells were stimulated with increasing concen-
trations of HMBA and the release of viral particles was
measured by p24 ELISA after 24 h in their supernatants. As
expected, HMBA induced viral production in a dose-depend-
ent manner in all cells examined (Figure 1A). At the optimal
concentration of HMBA, viral production in U1, ACH-2, and
JDK cells increased by 135-, 25-, and 220-fold, respectively.
Since viral production increased the most in JDK cells that
bear an integrated HIV genome lacking two NF-jB binding
sites, this stimulatory effect of HMBA did not depend on NF-
jB. At higher concentrations, HMBA was less efﬁcient at
inducing viral production, most likely due to its pronounced
cytotoxic effects as determined by trypan blue staining and
FACS analyses (not shown). In addition, HMBA induced an
increase of the luciferase activity from HeLa cells that
contained an integrated luciferase gene under the control
of the HIV promoter (not shown). We conclude that HMBA
induces viral production in chronically infected cell lines,
most likely through an NF-kB-independent activation of HIV
transcription.
To conﬁrm these effects on viral production in primary
cells, peripheral blood lymphocytes (PBLs) were activated for
3 d, infected with HIV-1LAI, and rested for 11 d. Next, resting
CD4þ T cells were isolated using anti-CD4 magnetic beads
and washed extensively. By FACS, these cells expressed
neither CD25 nor HLA-DR (not shown). Before the addition
of HMBA, we observed few if any viral particles in the
supernatants of these selected cells (Figure 1B, control). In
contrast, in the presence of HMBA, levels of p24 increased 7-
fold in their supernatants (Figure 1B, HMBA). Thus, HMBA
also activates viral production in resting CD4þ T cells.
HMBA Disrupts Transiently the LC
Previous studies established that HMBA activates HIV
transcription [14,15,34]. Moreover, HIV gene expression
depends critically on the kinase activity of P-TEFb [31].
Finally, HMBA induces the expression of HEXIM1 and
HEXIM2, which together with 7SK snRNA inhibit P-TEFb
in the LC [35]. Thus, HMBA could disrupt the LC, albeit
transiently, to activate P-TEFb for the stimulation of HIV
transcription. Therefore, we analyzed the LC and SC by
glycerol gradient sedimentation analyses with anti-HEXIM1,
HEXIM2, and P-TEFb antibodies at various times in Jurkat
cells that were treated with HMBA (Figure 1C). As described
previously, the presence of HEXIM1/2, CycT1, and Cdk9 in
high molecular weight fractions is characteristic of their
presence in the LC with 7SK snRNA [25]. As presented in
Figure 1C, HMBA induced the disruption of the LC (fractions
5, 6, and 7), starting as soon as 30 min and reaching a
maximum at 1 h after the addition of HMBA. Since HEXIM1,
HEXIM2, and Cdk9 reassociated into the LC as soon as 6 h
after the addition of HMBA, this disruption was transient.
Notably, the reassociation of P-TEFb with HEXIM1 was more
efﬁcient than the reassociation with HEXIM2. Also, whereas
overall amounts of HEXIM1 and HEXIM2 increased after 6 h
of stimulation, levels of Cdk9 did not change signiﬁcantly.
Quantitative data presented in Figure 1D demonstrate that
ratios between LC and SC (LC/SC) were minimal at 1 h and
came back to pre-treatment values at 6 h post-stimulation.
Thus, whereas HMBA disrupts the LC transiently in Jurkat
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Author Summary
The reservoir of HIV in infected people remains an insurmountable
problem in the era of highly active antiretroviral therapy. Thus, the
virus persists despite the best possible treatment. HIV hides in many
cells and tissues, where its genome is not expressed. Thus, neither
drugs nor the immune system can eradicate it from the body. One
hope is to activate the production of HIV in these reservoirs in the
presence of optimal treatment. Strategies aimed at activating
hematopoetic cells and thus viral replication have been tried and
failed. In this report, we targeted a specific host transcriptional
complex that is essential for the transcription of HIV genome. Its
activation should not lead to generalized stimulation of the immune
system. Indeed, paradoxically, hexamethylene bisacetamide (HMBA)
and related compounds lead to cellular differentiation and
apoptosis. By studying properties of these differentiation agents,
we discovered that they activate transiently transcription of HIV, be
it in stable cell lines or in primary infected cells. Thus, compounds
related to HMBA, some of which have now been approved for
clinical use, could be tried to diminish or eliminate the reservoir of
HIV in optimally treated infected individuals.cells, a prolonged exposure to this compound leads to the
establishment of a new equilibrium between LC and SC.
HMBA Induces Viral Production via the Activation of PI3K
and Akt
To determine the mechanism by which HMBA induced
such a rapid, transient disruption of the LC, we reasoned that
HMBA could act by activating cellular signaling pathways.
Since SAHA is similar in structure to HMBA [13,17] and it
activates the PI3K/Akt pathway [20], we hypothesized that
HMBA could do the same. Indeed, HMBA activated Akt
transiently in Jurkat cells as determined with an antibody that
recognizes the active, phosphorylated form of Akt (Figure
2A). This activation which was detected after 30 min of
stimulation, decreased signiﬁcantly at 6 h (Figure 2A, lanes 2–
4). Moreover, 24 h later, levels of activated Akt were even
lower than those in untreated cells (compare lanes 1 and 5).
Importantly, HMBA-mediated activation of Akt was inhibited
when cells were pre-incubated with the PI3K inhibitor
LY294002 (Figure 2A, lane 6) or the Akt inhibitor 8 (AI8,
Figure 2A, lane 7). Thus, similar to SAHA, HMBA induces a
transient activation of Akt via PI3K and results in a long-term
inhibition of this signaling pathway. Importantly, the kinetics
of Akt activation correlated nicely with the kinetics of
disruption of the LC.
To investigate this activation of Akt further, we next asked
whether these kinases were required for the stimulatory effect
of HMBA on viral production. We pre-incubated U1 cells
with AI8 or LY294002 prior to the stimulation with HMBA
and measured viral production as in Figure 1A. In these cells,
HMBA stimulated viral production by approximately 150-
fold (Figure 1A, lane 2). Critically, in U1 cells, inhibitors of
Figure 1. HMBA Transiently Disrupts the LC
(A) U1, Ach-2, and JDK cells were stimulated with increasing concentrations of HMBA (1, 5, 10, and 20 mM) and viral production was assessed at 48 h in
the supernatant using p24 ELISA.
(B) Resting CD4þT cells, which were isolated from PBMCs that were infected with HIV-1LAI and rested for 11 d were treated or not with HMBA (1 mM) for
3 d. Viral production was assessed using p24 ELISA.
(C) Total cell lysates of Jurkat cells stimulated or not with HMBA (5 mM) for 30 min, 1 h, 2 h, 6 h, and 24 h, were subjected to glycerol gradient
sedimentation analyses (10%–30%), and the fractions were analyzed by western blotting using HEXIM1, HEXIM2, and Cdk9 antibodies. Numbers below
the western blots correspond to fractions from glycerol gradient analyses.
(D) LC/SC represents the ratio of cumulated intensities of fractions 5, 6, and 7 (LC) over intensities of fractions 1, 2, and 3 (SC). Values were normalized to
ratios obtained in unstimulated cells.
doi:10.1371/journal.ppat.0020146.g001
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by 97% and 90%, respectively (Figure 2B, lanes 3 and 4). In
contrast, these inhibitors had only minor effects on basal
levels of viral production (lanes 5 and 6). Consistent with
these results, the expression of a mutant dominant negative
form of Akt (DN-Akt) also prevented the stimulation of viral
production by HMBA in U1 cells (Figure 2C, compare lanes 3
and 4). In addition, similar effects were observed in ACH-2
and JDK cells (not shown). Taken together, these results
demonstrate that a transient activation of the PI3K/Akt
pathway is required for the HMBA-induced viral production
in chronically infected cell lines.
HMBA Disrupts the LC via the Activation of the PI3K/Akt
Pathway
Thus far, our results indicated that HMBA disrupts the LC
transiently and that it induces viral production via PI3K and
Akt. To investigate whether the disruption of the LC by
HMBA was also dependent on the PI3K/Akt pathway, we pre-
incubated Jurkat cells with AI8 or LY294002 prior to the
stimulation with HMBA and followed the partitioning of
endogenous HEXIM1, HEXIM2, and P-TEFb in the LC and SC
by glycerol gradient sedimentation analyses as in Figure 1C.
Critically, both inhibitors prevented the HMBA-mediated
disruption of the LC (Figure 3A, lanes 3 and 4). Similarly,
when we expressed a mutant constitutively active form of Akt
(M-Akt), the LC was also disrupted (Figure 3B). Finally, in
addition to experiments performed in transformed cell lines,
we also examined effects of HMBA in primary lymphocytes.
As presented in Figure 3C, HMBA had the same effect on
partitioning of HEXIM1 and Cdk9 in LC and SC in these cells.
Moreover, AI8 also prevented the HMBA-induced disruption
of the LC. Taken together, these results demonstrate that
HMBA disrupts the LC via the activation of the PI3K/Akt
pathway in transformed cell lines and in primary cells.
Moreover, results from primary cells suggest that the
disruption of the LC is likely to be critical for the HMBA-
induced viral production in vivo.
HMBA Induces the Recruitment of P-TEFb to the HIV
Promoter and Promotes Transcription Elongation
Since HMBA disrupted the LC and thus released active P-
TEFb, we wanted to determine if the released SC could then
be recruited to the HIV promoter, leading to increased
transcription elongation of the viral genome. To test this
hypothesis, we followed occupancies of P-TEFb and RNAPII
on the HIV promoter and the downstream coding sequences
by performing chromatin immunoprecipitation assays
(ChIPs; Figure 4). Positions of primers used in our ChIPs
are depicted in Figure 4A. First, we stimulated JDK cells with
or without HMBA for 1 h in the presence or absence of AI8
prior to ChIPs. To detect P-TEFb and RNAPII, we used
antibodies directed against CycT1 and the large subunit of
RNAPII. Consistent with our ﬁndings that HMBA disrupts the
LC, P-TEFb was recruited efﬁciently to the HIV promoter
and coding region only upon the stimulation with HMBA,
whereas this event was inhibited in the presence of AI8
(Figure 4B, top panels). Moreover, whereas levels of RNAPII
increased markedly on the coding region in the presence of
HMBA, AI8 prevented this effect (Figure 4B, bottom panel).
Notably, HMBA stimulation resulted in a slightly decreased
occupancy of RNAPII on the HIV promoter, possibly
reﬂecting increased rates of transcription elongation. In
contrast, the presence of AI8 abolished this decrease. We
conclude that HMBA disrupts the LC in a PI3K/Akt-depend-
ent manner to release P-TEFb that is then recruited to the
HIV promoter and coding sequences. Consequently, RNAPII
elongates successfully on the viral genome. Moreover, as these
ﬁndings were obtained in JDK cells that contained an
Figure 2. HMBA Induces HIV Production from Latently Infected Cell Lines
via the PI3K/Akt Pathway
(A) Total cell lysates of Jurkat cells preincubated or not with inhibitors of
Akt or PI3K (AI8 or LY294002) and stimulated or not by HMBA (5 mM) for
30 min, 1 h, 6 h, and 24 h were analyzed by western blotting using anti-
phospho-Akt antibodies, or Anti-Akt antibodies for loading controls.
(B) U1 cells were cultured in the presence or absence of LY294002 (10
lM) or AI8 (1 lM) prior to stimulation with HMBA (5 mM). Concentrations
of p24 antigens were then measured from supernatants at 24 and 48 h
after stimulation to assess viral production.
(C) U1 cells were transfected with a plasmid expressing a dominant
negative mutant Akt protein (DN-Akt) or with an empty plasmid vector.
After 24 h, cells were stimulated or not with HMBA (5 mM) and viruses in
the supernatant were quantified 24 h later using p24 ELISA. Lower panels
represent the levels of DN-Akt expressed in cells as assessed using glu-
glu tag antibodies.
doi:10.1371/journal.ppat.0020146.g002
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results suggest further that the stimulation of HIV tran-
scription by HMBA can occur independently of NF-jB.
Conserved Threonine and Serine Residues in the CycT-
Binding Domain of HEXIM1 Are Critical for P-TEFb Binding
To demonstrate formally that observed effects of HMBA
were mediated via the disruption of the LC, we next wanted
to gain insight into the mechanism of this process. Impor-
tantly, when present in the LC, the CycT1 subunit of P-TEFb
binds HEXIM1 directly via its CycT-binding domain (TBD)
[33]. Since the activation of the PI3K/Akt pathway is required
for the disruption of the LC, we reasoned that an active
cellular kinase might target conserved residues in HEXIM1,
whose phosphorylation could abrogate the binding between
HEXIM1 and P-TEFb. Indeed, an inspection of the primary
TBD sequences in HEXIM1 and HEXIM2 from different
species identiﬁed a cluster of closely positioned serine and
threonine residues that could be targeted by the PI3K/Akt
pathway (Figure 5A). In HEXIM1, these included serines at
positions 268 (S268) and 278 (S278) and threonines at
positions 270 (T270) and 276 (T276). Next, mutant Flag
epitope-tagged HEXIM1 proteins were generated, in which
these four residues were replaced by alanines (f:Hex1(4A)) or
aspartic acid (f:Hex1(4D)), individually or in combination.
Since alanines cannot be phosphorylated, we reasoned that
some of these mutant HEXIM1 proteins should resist HMBA-
mediated disruption of the LC and should antagonize its
effects in cells. On the other hand, since aspartic acid mimics
constitutively phosphorylated residues, some of these mutant
f:Hex1 proteins should fail to bind P-TEFb in the LC.
First, we analyzed the binding and inhibitory properties of
these mutant f:Hex1 proteins in cells (Figure 5B and 5C). To
examine their binding to P-TEFb, wild-type and mutant
f:Hex1 proteins that contained serines and threonines
substituted in combination (f:Hex1(4A) and f:Hex1(4D)) or
individually (f:Hex1(268D), f:Hex1(270D), f:Hex1(276D), and
Figure 3. HMBA Disrupts the LC via the PI3K/Akt Pathway
Jurkat cells were stimulated or not with HMBA (5 mM) for 1 h in the
presence or absence of LY294002 (10 lM) or AI8 (1 lM) in (A) or were
electroporated with the empty plasmid vector or a vector expressing M-
Akt for 24 h in (B). Total cell lysates were then subjected to glycerol
gradient sedimentation and fractions were analyzed as in Figure 1.
Western blotting was performed using anti-HEXIM1 antibodies. Results
present the ratio LC/SC as in Figure 1. In (C), a similar analysis was
performed using total cell lysates of non-adherent PBMCs pre-treated or
not with AI8 and stimulated or not with HMBA (5 mM) for 30 min, 1 h,
and 2 h.
doi:10.1371/journal.ppat.0020146.g003
Figure 4. HMBA Induces the Recruitment of P-TEFb to the HIV Promoter
(A) Schematic representation of the HIV promoter (LTR) and coding
region (Gag). Lack of NF-jB sites is denoted by DjB. LTR: long terminal
repeat; Sp1: 3 Sp1 binding sites; T: TATA box; I: initiator; TAR,
transactivation response element; Gag: group specific antigen.
(B) JDK cells, chronically infected with HIV-1 lacking NF-jB binding sites,
were pre-treated or not with AI8 prior to the stimulation with HMBA (5
mM, 1 h) and proteins were fixed onto DNA with formaldehyde.
Following sonication, the anti-CycT1 or anti-RNAPII antibodies were
added to the chromatin solution for immunoprecipitation of DNA–
protein complexes. PCR was performed with the indicated primers (A) to
analyze amounts of DNA that were associated with CycT1 or RNAPII at
the promoter (primer 1) or 1,000 nt downstream in the Gag gene (primer
2). Quantitative PCRs were performed with anti-RNAPII or anti-CycT1-
immunoprecipitated samples, as well as with input DNA before
immunoprecipitation, which served as controls for the amplification
efficiency of individual sets of PCR primers. Immunoprecipitates obtained
without using any antibody were used as negative controls.
doi:10.1371/journal.ppat.0020146.g004
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precipitated using anti-Flag agarose beads. The presence of
P-TEFb in immunoprecipitations was followed by antibodies
directed against CycT1. As expected, whereas wild-type and
mutant f:Hex1(4A) proteins bound P-TEFb, the mutant
f:Hex1(4D) protein failed to do so (Figure 5B, lanes 2–4).
Interestingly, whereas the mutant f:Hex1(268D) and
f:Hex1(276D) proteins did not alter these interactions, the
mutant f:Hex1(270D) and f:Hex1(278D) proteins did not
interact as potently (67% and 62% inhibition, respectively) as
the wild-type protein with P-TEFb, suggesting that T270 and
S278 are important for this interaction. Levels of Flag
epitope-tagged proteins in our immunoprecipitations were
similar (Figure 5B, lower panel). Moreover, individual alanine
substitutions did not affect the binding of the mutant f:Hex1
proteins to P-TEFb (not shown). Additionally, in contrast to
the wild-type and mutant f:Hex1(4A) proteins, the mutant
f:Hex1(4D) protein failed to bind P-TEFb in the LC as
determined by glycerol gradient sedimentation analyses (not
shown; see below).
Next, these features were supported further by transcrip-
tional assays in cells (Figure 5C). We used a classical DNA-
tethering system, which consists of the plasmid reporter
pG6TAR that contains six Gal4 DNA binding sites and the
plasmid effector Gal4.CycT1. The recruitment of Gal4.CycT1
to the promoter results in the P-TEFb-dependent activation
of transcription that is sensitive to the inhibition by HEXIM1
[28]. Indeed, the mutant f:Hex1(4A) protein inhibited the
transcriptional activation by Gal4.CycT1 even more robustly
when compared to the wild-type f:Hex1 protein (Figure 5C,
lanes 1–3). In contrast, the mutant f:Hex1(4D) protein, which
failed to bind P-TEFb, did not inhibit this transcriptional
activation (Figure 5C, lane 4). Similar results were obtained
with mutant f:Hex1(270D) and f:Hex1(278D) proteins. Also,
levels of Flag epitope-tagged proteins were similar (Figure 5C,
lower panel). Collectively, these results indicate that T270 and
S278 in the TBD of HEXIM1 are important for its binding to
P-TEFb in cells. Furthermore, they suggest that these residues
could be phosphorylated by Akt, leading to the disruption of
the LC and a subsequent release of the transcriptionally
active P-TEFb.
T270 and S278 in the TBD of HEXIM1 Are Targeted by the
PI3K/Akt Pathway
To examine directly whether HEXIM1 is phosphorylated by
Akt in cells, the wild-type and mutant f:Hex1(4A) proteins
were expressed in the presence or absence of the mutant
constitutively active form of Akt (M-Akt) in Jurkat cells. Cell
extracts were subjected to immunoprecipitation as above
using anti-Flag agarose beads. Western blotting with anti-
bodies directed against phospho-Akt substrates revealed that
the wild-type f:Hex1 protein was phosphorylated extensively
only when co-expressed with the mutant M-Akt protein
(Figure 6A, lane 3 and 6B, lane 7), whereas in its absence only
a modest phosphorylation was detected (Figure 6A, lane 1 and
6B, top left panel). In sharp contrast, the mutant f:Hex1(4A)
protein was not phosphorylated even in the presence of the
mutant M-Akt protein (Figure 6A, lane 4). Importantly,
whereas phosphorylation of the mutant f:Hex1(268A) and
f:Hex1(276A) proteins was not affected, the phosphorylation
of the mutant f:Hex1(270A) and f:Hex1(278A) proteins was
signiﬁcantly reduced (50% and 69%, respectively) when
compared to the wild-type f:Hex1 protein (Figure 6, compare
lanes 8 and 10 to lanes 9 and 11). Finally, when both T270 and
S278 were substituted with alanines, which yielded the
mutant f:Hex1(2A) protein, the phosphorylation was reduced
even further (Figure 6B, lane 12). Also, immunoprecipitated
Flag epitope-tagged proteins were detected at similar
amounts (Figure 6A and 6B, lower panel). Taken together,
these ﬁndings demonstrate that HEXIM1 is phosphorylated
upon Akt activation in Jurkat cells and that the T270 and
Figure 5. Mutant f:Hex1(4D) Protein Is Functionally Inactive
(A) Schematic representation of HEXIM1. Sequences are representative of
mutant f:Hex1(4A) and f:Hex1(4D) proteins. Mutations are underlined. ID:
inhibitory domain; BR: basic region; AR: acidic region; TBD, CycT-binding
domain.
(B) Extracts prepared from Jurkat cells transfected with an empty plasmid
vector or those expressing f:Hex1, mutant f:Hex1(4A), or f:Hex1(4D)
proteins, or point mutant f:Hex1(268D), f:Hex1(270D), f:Hex1(276D), or
f:Hex1(278D) proteins, were subjected to anti-Flag immunoprecipitation.
Levels of endogenous CycT1 protein bound to Flag epitope-tagged
mutant HEXIM1 proteins are indicated in the upper panel. The middle
panel represents levels of Flag epitope-tagged mutant HEXIM1 proteins
expressed in Jurkat cells and the lower panel shows the input of CycT1.
(C) Jurkat cells were co-transfected with the reporter plasmid pG6TAR
(0.4 lg) and, where indicated, with the plasmids expressing Gal4.CycT1
(0.6 lg), f:Hex1 (0.8 lg), f:Hex1(4A) (0.8 lg), f:Hex1(4D) (0.8 lg),
f:Hex1(268D) (0.8 lg), f:Hex1(270D) (0.8 lg), f:Hex1(276D) (0.8 lg), or
f:Hex1(278D) (0.8 lg). Error bars represent the meanþ/ SD. Lower panel
presents the levels of Flag epitope-tagged HEXIM1 proteins expressed in
Jurkat cells.
doi:10.1371/journal.ppat.0020146.g005
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results suggest that the phosphorylation of residues in the
TBD of HEXIM1 via the PI3K/Akt pathway disrupts the LC.
Conserved Threonines and Serines in the TBD of HEXIM1
Mediate Its Release from the LC
To determine whether conserved threonines and serines
were required for the HMBA-mediated disruption of the LC,
we expressed the wild-type or the mutant f:Hex1(4A) proteins
in Jurkat cells. As in Figure 1, the partitioning of f:Hex1
proteins in the LC and SC in untreated or HMBA-treated
cells was followed by glycerol gradient sedimentation analyses
(Figure 7A). Similar to endogenous HEXIM1 proteins, the
wild-type f:Hex1 protein was released from the LC upon
HMBA stimulation and the Akt inhibitor AI8 prevented this
effect (Figure 7A, lanes 1–3). Critically, the mutant f:Hex1(4A)
protein was not responsive to HMBA treatment and
remained in the LC even after the stimulation (Figure 7A,
lanes 4 and 5). Taken together, these results demonstrate that
the conserved threonines and serines in the TBD play a major
role in regulating the release of HEXIM1 from the LC upon
HMBA stimulation of cells.
HMBA Stimulation of Viral Production Depends on T270
and S278 in the TBD of HEXIM1
Finally, the use of the mutant f:Hex1(4A) protein that
resisted the HMBA-mediated disruption of the LC enabled us
to examine directly the importance of this phosphorylation
for the stimulation of viral production. Wild-type or mutant
f:Hex1(4A) proteins were expressed in U1 cells that were left
untreated or treated with HMBA, and the production of new
viral particles was measured as above. As presented in Figure
7B, the expression of the mutant f:Hex1(4A) protein
antagonized effects of HMBA profoundly, as its induction
of viral production was decreased by 75% (Figure 7B, lane 8).
Consistently, individual substitutions of the threonine and
serine at positions 270 and 278 with alanines reduced viral
production by 50% and 40% in the presence of HMBA
(Figure 7B, lanes 4 and 6), and mutation of both residues
(f:Hex1(2A)) resulted in an inhibition comparable to that by
the mutant f:Hex1(4A) protein (Figure 7B, compare lanes 7
and 8). In contrast, HMBA induced viral production robustly
and the expression of the wild-type f:Hex1 protein had only a
modest effect (Figure 7B, lanes 1 and 2). Also, levels of these
Flag epitope-tagged proteins were similar as were basal levels
of viral production in these cells (Figure 7B, lower panel and
lanes 1–8). Taken together, these results indicate that HMBA
induces viral production via the PI3/Akt pathway and the
disruption of the LC via the phosphorylation of the T270 and
S278 of HEXIM1.
Discussion
In this study, we demonstrated that HMBA reactivates viral
production in chronically infected cells via the transient
release of active P-TEFb from the LC. These events depended
on the transient activation of the PI3K/Akt pathway that led
to the phosphorylation of T270 and S278 in HEXIM1. In turn,
the released P-TEFb was recruited to the HIV promoter to
stimulate transcription elongation. Importantly, the inhib-
ition of the PI3K/Akt pathway and the transient expression of
mutant HEXIM1 proteins that could not be phosphorylated
and released from the LC via Akt antagonized the HMBA-
mediated induction of viral production. Therefore, we
provide a mechanism by which HMBA targets the pivotal
cellular co-factor P-TEFb for the reactivation of HIV.
Thus far, a regulatory mechanism that releases P-TEFb
from HEXIM1 and 7SK snRNA has not been determined.
Here, we provide evidence that HMBA accomplishes this task
by activating the PI3K/Akt pathway. Since inhibitors of both
kinases and the expression of the mutant DN-Akt protein
resulted in an identical phenotype, PI3K and Akt are involved
in this release. Moreover, the mutant constitutively active M-
Akt protein also released P-TEFb. It is attractive to
hypothesize that HMBA, which is a bipolar compound, binds
and activates PI3K directly or via aggregation. In such a
scenario, the brief nature of this signal could reﬂect a rapid
modiﬁcation of HMBA and/or the sequestration and degra-
dation of the signaling complex. The signaling pathway
between PI3K and Akt and the subsequent nuclear trans-
location of Akt has been described in great detail elsewhere
[36]. Since the mutant constitutively active M-Akt protein led
to the phosphorylation of T270 and S278, it is tempting to
speculate that Akt could phosphorylate these residues in the
TBD of HEXIM1 directly. This phosphorylation also abro-
gated the binding between HEXIM1 and P-TEFb in cells.
Indeed, this ﬁnding was supported by the analysis of mutant
HEXIM1 proteins containing aspartic acids that mimic
Figure 6. T270 and S278 in the TBD of HEXIM1 Are Phosphorylated following the Activation of Akt In Vivo
f:Hex1 protein and mutant f:Hex1(4A) protein in (A), and mutant f:Hex1(268A), f:Hex1(270A), f:Hex1(276A), or f:Hex1(278A) proteins in (B) were
expressed in Jurkat cells transfected with an empty plasmid vector or a vector expressing M-Akt. After 24 h, protein extracts were subjected to
immunoprecipitation using anti-Flag antibodies, and levels of phospho-Akt substrates (pAktSub) and Flag-tagged expressed proteins were measured
by western blotting.
doi:10.1371/journal.ppat.0020146.g006
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inhibited P-TEFb. Notably, these residues are positioned in
close proximity to the ﬁrst coiled coil segment in the TBD,
which is critical for CycT1 binding [26,37]. Thus, it is
conceivable that the introduction of two negative charges
by phosphorylation changed the structure of the adjacent
ﬁrst coiled coil segment, leading to the loss of binding
between P-TEFb and HEXIM1 in cells. Finally, although the
PI3K/Akt pathway also activates NF-jB [38], it is unlikely that
it was responsible for the recruitment of P-TEFb to the HIV
promoter in JDK cells that lacked NF-jB-binding sites.
Indeed, a previous study by Antoni et al. reached the same
conclusion [15]. Rather, the recruitment of P-TEFb could
have been achieved via other transcription factors that bind
the HIV promoter, such as NF-AT, AP-1, LEF-1, and/or Brd4
[30,39].
Elucidating how HMBA mediates the disruption of the LC
reveals one mechanism by which cells can regulate the release
of active P-TEFb from HEXIM1 and 7SK snRNA. How other
agonists such as stress-inducing agents and inducers of
cardiac hypertrophy disrupt the LC remains unknown
[23,30,33,34,40]. However, some of them could signal via
receptor tyrosine kinases and other cellular kinases, i.e., they
could also access the PI3K/Akt pathway. Moreover, our study
also does not preclude that other RNA–protein and protein–
protein interactions in the LC could be targeted via
additional posttranslational modiﬁcations, which would also
disrupt the LC [24,26–28,41].
A large body of evidence demonstrates that several differ-
ent mechanisms can maintain HIV latency at the level of
transcription (reviewed in [1,2]). These include changes in
chromatin structure, transcription interference, insufﬁcient
levels of activators, P-TEFb, and/or the absence of the
functional viral transcriptional transactivator Tat on the
HIV promoter. Interfering with many of these mechanisms
can reactivate latent HIV. Our study and those of others also
suggest that this induction can be achieved by exposing
latently infected cells to HMBA. Although HMBA is not an
HDAC inhibitor, we found that it increases levels of P-TEFb
on the HIV promoter, which led to the elongation of RNAPII
that is accompanied by remodeling of the local chromatin
structure. The disruption of the equilibrium between active
and inactive P-TEFb by HMBA was transient, yet the resulting
induction of HIV transcription persisted. This ﬁnding can be
explained by the order of events that follow HMBA
stimulation. During the ﬁrst hours of HMBA treatment, the
abundance of active P-TEFb leads to viral transcription in the
absence of Tat. Since Tat releases P-TEFb from the LC by
virtue of competing effectively with HEXIM1 and 7SK snRNA
for binding to P-TEFb [42,43], its synthesis blunts effects of
the reassembly of the LC. Thus, in the presence of Tat, HIV
transcription continues despite modiﬁcations in the distri-
bution of P-TEFb between the SC and LC.
How does our work contribute to a possible therapeutic
use of HMBA and related bipolar compounds to purge the
latent viral reservoir? Despite the fact that HMBA induced
HIV transcription and production, we could not detect viral
production in primary CD4þ T lymphocytes isolated from
optimally treated individuals, most likely because this com-
pound also interferes with the de novo infection ([16] and our
results). Thus, HIV could not spread from a small number of
infected cells (one in 10
6 latently infected cells, [44]).
However, we were able to demonstrate that HMBA could
activate viral production in resting primary CD4þ T cells.
Although these ﬁndings precluded the ampliﬁcation of
detectable viral particles, they represent yet another advant-
age for the potential therapeutic use of these agents. Thus,
HMBA not only reactivates viral production but also inhibits
new infection. Unfortunately, HMBA can not be used
therapeutically as it is too toxic for human use. Alternatively,
other bipolar compounds structurally related to HMBA
might be tried, such as SAHA, which also activates the
PI3K/Akt pathway [20]. Importantly, SAHA has been ap-
proved recently for the treatment of human cutaneous T cell
lymphoma [45] and could thus be used alone or in
combination with other therapies.
Finally, our ﬁndings might also shed a new light onto how
modiﬁcations in the equilibrium between active and inactive
P-TEFb complexes could affect cell growth, proliferation, and
differentiation. HMBA induces the differentiation of many
cells, including murine erythroleukemic and vascular smooth
Figure 7. Mutation of the Conserved Threonines and Serines Renders
HEXIM1 Insensitive to HMBA Treatment and Antagonizes the Induction
of HIV Production by HMBA
(A) Jurkat cells were transfected with plasmids expressing wild-type
f:Hex1 or mutant f:Hex1(4A) proteins and then stimulated or not with
HMBA (5 mM) for 1 h in the presence or absence of AI8 (1 lM). Total
lysates were then subjected to glycerol gradient sedimentation and
fractions were analyzed as in Figure 2. Western blot was performed using
anti-Flag antibodies and the ratio LC/SC measured as in Figure 1.
(B) U1 cells were transfected with an empty plasmid vector or those
expressing mutant f:Hex1, f:Hex1(2A), f:Hex1(4A), f:Hex1(268A),
f:Hex1(270A), f:Hex1(276A), or f:Hex1(278A) proteins. After 24 h, cells
were stimulated or not with HMBA (5 mM), supernatant collected after
another 24 h, and virus quantified using p24 ELISA.
doi:10.1371/journal.ppat.0020146.g007
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HMBA Activates PI3K, Akt, and HIV Productionmuscle cells, monocytes, lymphocytes, and neurons [46,47].
Importantly, HMBA also increases greatly the expression of
HEXIM1 in vascular smooth muscle cells [22] and more
recently, the transient disassembly and reassembly of the LC
by HMBA was found to be associated with the differentiation
of murine erythroleukemic cells [34]. Indeed, whereas the
sustained activation of PI3K and Akt is associated with cell
growth and proliferation [48], a transient activation of the
PI3K/Akt pathway leads rather to cell differentiation and
growth arrest. This seeming paradox can now be explained by
the feedback mechanism involved in the regulation of P-
TEFb. We propose that HMBA ﬁrst disrupts the LC to release
the active P-TEFb, which is followed by increased global
transcription. In very short order, the LC reassembles with
abundant new synthesis of HEXIM1 [22,34]. As the pool of
active P-TEFb decreases, cellular reprogramming follows,
leading to cell differentiation. As SAHA also activates
transiently this pathway [20], the role of other bipolar
compounds that are related to HMBA should also be
investigated for their effects on PI3K and Akt.
Materials and Methods
Cell lines. U1, ACH-2, and J1.1 cells were obtained through the
NIH AIDS reagents program. JDK cells were kindly provided by
Arnold Rabson. Jurkat. U1, ACH-2, J1.1, and JDK cells were grown in
RPMI containing penicillin (100 IU/ml), streptomycin (100 lg/ml), and
10% FBS at 37 8C with 5% CO2.
Plasmid DNAs. Plasmid reporter pG6TAR and plasmids coding for
the Gal4.CycT1 chimera or f:Hex1 protein were described previously
[28]. To construct plasmids coding for the mutant f:Hex1 proteins,
the pFlag-CMV-2. HEXIM1 plasmid was subjected to site directed
mutagenesis with the QuickChange II XL Site-Directed Mutagenesis
Kit (200521; Stratagene). The plasmids coding for myristoylated Akt
(M-Akt) and dominant negative Akt (DN-Akt) were a gift from David
Stokoe and were described previously [49].
Immunoreagents and chemicals. The anti-CycT1 (sc-8127) and
anti-Cdk9 (D7) antibodies were obtained from Santa Cruz Biotech-
nology. The anti-HEXIM1 and anti-HEXIM2 antibodies were
described previously [26]. The antibodies directed against the total
(9272), phosphorylated form of Akt (9271), and phospho-Akt
substrates (9611S) were obtained from Cell Signaling. DN-Akt and
M-Akt were a gift from David Stokoe [49]. The anti-Flag M2 (F3165)
antibody and the anti-Flag M2 beads (FlagIPT-1) were purchased
from Sigma-Aldrich.
HMBA (Sigma-Aldrich) was resuspended in sterile water to obtain
a stock solution of 1 M. Chemical inhibitors, Akt inhibitor VIII (AI8),
and LY 294002 (Calbiochem), were resuspended in DMSO.
Activation of HIV production in HIV chronically infected cell lines.
U1, ACH-2, or JDK cells were plated at 2.10
5 cells/ml in 24-well plates,
supernatant was collected before stimulation with HMBA and then
every day, and viral release in the supernatant quantiﬁed by p24
ELISA (PerkinElmer). Baseline levels were of 50 to 100 pg/ml in
control cells. Pre-treatment with inhibitor was done 1 h before
stimulation by HMBA. Plasmid transfection was done using Gene
Pulser II Electroporator (Bio-Rad).
Transient transfection and CAT reporter gene assay. HeLa cells
were seeded into six-well plates approximately 12 h prior to
transfection and transfected with FuGENE6 reagent (1 815 091;
Roche Applied Science). CAT enzymatic assays were performed as
described [28]. Transcriptional activation of the pG6TAR reporter
plasmid by the Gal4.CycT1 chimera was set to 100%. Error bars give
standard errors of the mean.
Immunoprecipitation assay and western blotting. 10 millions of
Jurkat cells were lysed in 0.8 ml of lysis buffer A (10 mM Tris-HCl [pH
7.4], 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% protease inhibitor)
for 0.5 h at 4 8C 20 h post-electroporation. The lysates were
immunoprecipitated with the anti-Flag M2 beads for 2 h at 4 8C,
washed extensively with the lysis buffer A, and the bound proteins
were separated on SDS-PAGE electrophoresis. Western blotting was
performed with the indicated antibodies and according to the
standard protocols.
Glycerol gradient sedimentation analysis. Glycerol gradients
(10%–30%) were established by pippeting 2 ml of each of the
glycerol fractions (10, 15, 20, 25, and 30% v/v) in buffer A (20 mM
HEPES [pH 7.9], 0.3 M KCl, 0.2 mM EDTA, 0.1% NP-40) into
centrifugation tubes (Beckman), 331372. Gradients were formed by
standing for 6 h at 4 8C. HeLa cells either transfected with the
corresponding plasmids or not transfected were lysed in 0.5 ml of
buffer A containing 0.1% protease inhibitor and either 0.5% RNase
inhibitor or RNase A (100 mg/ml ﬁnal concentration) for 30 min at 4
8C. The lysates were centrifuged at 10,000g for 10 min and the
supernatants were loaded into tubes with the preformed glycerol
gradients. Protein complexes were then fractionated by centrifuga-
tion in an SW 41Ti rotor (Beckman) at 38,000 rpm. for 21 h. Ten
fractions (1 ml) were collected, precipitated with trichloracetic acid
and ﬁnally analyzed by immunoblotting with the appropriate
antibodies [25]. Films with exposures in the linear range were used
and intensities of each bands were obtained using histograms with
Photoshop. The ratio of proteins present in the LC (fractions 5, 6, and
7) versus the ones present in the SC (fractions 1, 2, and 3) was
calculated. The ratio LC/SC was normalized to 1 for unstimulated
cells.
Infection of PBMCs and isolation of resting CD4þ T cells. PBMCs
were isolated from buffy coats of healthy HIV negative donors in a
Ficoll density gradient (Pharmacia). PBMCs were then plated at 5.10
6
cells per ml in 24-well plates, using RPMI 10% human serum AB.
After 30 min, non-adherent cells (PBLs) were isolated and cultured in
complete RPMI (containing penicillin [100 IU/ml], streptomycin [100
lg/ml], and 10% FCS) with IL-2 (10 U/ml) and PHA (3 ug/ml). After 3
d, cells were treated or not with HMBA (5 mM) in the presence or
absence of Akt inhibitor 8 (AI8).
After isolation, PBLs (10
7) were activated with PHA (5 lg/ml) and
IL-2 (10 U/ml) for 3 d and infected with HIV-1LAI (0.1 ng/ml of p24).
They were cultured in RPMI, 10% FCS, supplemented with IL-2 (10
U/ml). After 11 d, resting CD4þ T cells were isolated by negative
selection using magnetic beads (Invitrogen). Cells were more
than 95% pure as assessed by FACS. These cells were then cultured
in RPMI, 10% FCS. These cells expressed neither CD25 nor HLA-
DR.
ChIP assays. ChIP was carried out essentially as described
previously [50]. Cross-linking was achieved by incubating 70 million
cells (J1.1 or JDK) in 1% formaldehyde in medium for 10 min at room
temperature. Cross-linking reactions were stopped by addition of
glycine to a ﬁnal concentration of 0.125 M. Cells were then pelleted in
a conical tube and washed with cold phosphate-buffered saline. The
cell pellets were then resuspended in 1 ml of Lysis buffer (1% SDS, 10
mM EDTA, 50 mM Tris-HCl [pH 8.0]) for 10 min on ice and subjected
to sonication to obtain DNA fragments averaging approximately 200
to 500 bp in length. One-tenth of the total chromatin solution was
used in each ChIP. Chromatin solutions were precleared with protein
A/G-Sepharose beads and then incubated with the appropriate
antibody at 4 8C overnight. Protein A/G-Sepharose beads were then
added, and the mixture was incubated for another 2 h. The beads
were washed ﬁve times in TSE-150 (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris-HCl [pH 8.0], 150 mM NaCl), TSE-500 (like
TSE-150 but with 500 mM NaCl), and buffer III (0.25 M LiCl, 1% NP-
40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl [pH 8.0]), and
twice in Tris-EDTA buffer. Immunocomplexes were eluted from the
beads with elution buffer (1% SDS and 0.5% NaHCO3) for 15 min at
RT. The DNA–protein complexes were then treated with proteinase
K, followed by reverse cross-linking at 65 8C 4 h. DNA was extracted
with phenol-chloroform, precipitated with ethanol, and dissolved in
30 ll of Tris-EDTA buffer. Two microliters of DNA was used with
appropriate primer sets to amplify speciﬁc DNA fragments. qPCR
was then performed using the Stratagene MX3000P real-time PCR
system. Primers used for LTR were described previously [8] and
primers for Gag span a region comprised between nucleotides 1144
and 1410. Standard curves for each primer pair was ﬁrst obtained to
check for their respective efﬁciency. Products were quantiﬁed using
Brilliant SYBR Green QPCR (Stratagene) according to the manu-
facturer’s directions. Relative intensity was calculated and normalized
to the input. Fold-induction was assessed as the immunoprecipitation
with speciﬁc antibodies over no antibody control.
Supporting Information
Accession Numbers
The National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/) accession numbers for HEXIM1 are NM_006460
(nucleotide sequence) and BAA36166 (protein sequence).
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